AVE-1625 – 10 mg

Brand:
Cayman
CAS:
358970-97-5
Storage:
-20
UN-No:
Non-Hazardous - /

The central cannabinoid (CB1) receptor is a G protein-coupled receptor that is widely distributed in the central nervous system and several peripheral tissues and binds the active component of cannabis, Δ9-tetrahydrocannabinol.{6749} Signaling through the CB1 receptor is implicated in attentional and working memory deficits as well as obesity.{12559,14939,15542} AVE-1625 is a highly potent, selective antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM.{15542} At 1-3 mg/kg, AVE-1625 significantly improves the performance of rodents in working memory tasks.{15542} At 30 mg/kg, AVE-1625 reduces caloric intake by more than 50% of controls and significantly increases lipolysis from fat tissues and reduces hepatic glycogen levels in rodents.{15541}  

 

Available on backorder

SKU: 10009021 - 10 mg Category:

Description

Potent and selective antagonist for the CB1 receptor (Ki = 0.16-0.44 nM); a dose of 1-3 mg/kg improves the performance of rodents in working memory tasks; a dose of 30 mg/kg reduces caloric intake, increases lipolysis from fat tissues and reduces hepatic glycogen levels in rodents


Formal name: N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-methanesulfonamide

Synonyms:  Drinabant

Molecular weight: 497.4

CAS: 358970-97-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors